Home LiteratureArticle Details
PMID: 11036002 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review

A neutrophil-derived anti-infective molecule: bactericidal/permeability-increasing protein.

Antimicrobial agents and chemotherapy ·Vol. 44 ·No. 11 ·2000-11-00 ·Pages 2925-31

Levy O

Abstract

暂无摘要

MeSH Terms
Anti-Infective Agents/pharmacology Antimicrobial Cationic Peptides Blood Bactericidal Activity Blood Proteins/pharmacology Clinical Trials as Topic Humans Membrane Proteins Neutrophils/chemistry
Chemicals
Anti-Infective Agents Antimicrobial Cationic Peptides Blood Proteins Membrane Proteins bactericidal permeability increasing protein
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Levy O
Division of Infectious Disease and General Clinical Research Center, Children's Hospital, Boston, Massachusetts 02115, USA. levy_o@al.tch.harvard.edu
References (62)
62 references, click to expand
  1. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group.
    Lancet. 2000 Sep 16;356(9234):961-7 PMID: 11041396
  2. Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease.
    J Clin Invest. 1998 Nov 15;102(10):1882-91 PMID: 9819375
  3. The role of lipopolysaccharides in the action of the bactericidal/permeability-increasing neutrophil protein on the bacterial envelope.
    J Immunol. 1984 Jun;132(6):3109-15 PMID: 6373924
  4. Oxygen-independent intracellular and oxygen-dependent extracellular killing of Escherichia coli S15 by human polymorphonuclear leukocytes.
    J Clin Invest. 1985 Jul;76(1):206-12 PMID: 3894419
  5. Preferential binding of the neutrophil cytoplasmic granule-derived bactericidal/permeability increasing protein to target bacteria. Implications and use as a means of purification.
    J Immunol. 1989 Apr 15;142(8):2807-12 PMID: 2539411
  6. Cloning of the cDNA of a human neutrophil bactericidal protein. Structural and functional correlations.
    J Biol Chem. 1989 Jun 5;264(16):9505-9 PMID: 2722846
  7. Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity.
    J Immunol. 1990 Jan 15;144(2):662-6 PMID: 2295804
  8. Separation of sublethal and lethal effects of the bactericidal/permeability increasing protein on Escherichia coli.
    J Clin Invest. 1990 Mar;85(3):853-60 PMID: 2179269
  9. Separation of sublethal and lethal effects of polymorphonuclear leukocytes on Escherichia coli.
    J Clin Invest. 1990 Aug;86(2):631-41 PMID: 2200807
  10. Human bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria.
    J Clin Invest. 1992 Sep;90(3):1122-30 PMID: 1522221
  11. High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide.
    Infect Immun. 1992 Nov;60(11):4754-61 PMID: 1398985
  12. Effect of lipopolysaccharide (LPS) chain length on interactions of bactericidal/permeability-increasing protein and its bioactive 23-kilodalton NH2-terminal fragment with isolated LPS and intact Proteus mirabilis and Escherichia coli.
    Infect Immun. 1994 Jan;62(1):259-65 PMID: 8262637
  13. Bactericidal/permeability-increasing protein and lipopolysaccharide (LPS)-binding protein. LPS binding properties and effects on LPS-mediated cell activation.
    J Biol Chem. 1994 Jul 1;269(26):17411-6 PMID: 7517398
  14. Individual and synergistic effects of rabbit granulocyte proteins on Escherichia coli.
    J Clin Invest. 1994 Aug;94(2):672-82 PMID: 8040321
  15. Relative concentrations of endotoxin-binding proteins in body fluids during infection.
    Lancet. 1994 Aug 13;344(8920):429-31 PMID: 7520106
  16. Bactericidal/permeability-increasing protein protects vascular endothelial cells from lipopolysaccharide-induced activation and injury.
    Infect Immun. 1994 Sep;62(9):3930-6 PMID: 8063410
  17. The respiratory burst oxidase.
    J Biol Chem. 1994 Oct 7;269(40):24519-22 PMID: 7929117
  18. Protective effects of a recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in an animal model of gram-negative sepsis.
    J Infect Dis. 1995 Jan;171(1):153-60 PMID: 7798655
  19. Integration of antimicrobial host defenses: role of the bactericidal/permeability-increasing protein.
    Trends Microbiol. 1994 Sep;2(9):324-8 PMID: 7812665
  20. Extracellular accumulation of potently microbicidal bactericidal/permeability-increasing protein and p15s in an evolving sterile rabbit peritoneal inflammatory exudate.
    J Clin Invest. 1995 Apr;95(4):1916-24 PMID: 7706499
  21. Antibacterial proteins of granulocytes differ in interaction with endotoxin. Comparison of bactericidal/permeability-increasing protein, p15s, and defensins.
    J Immunol. 1995 May 15;154(10):5403-10 PMID: 7730641
  22. Inhibition of endotoxin-induced activation of the coagulation and fibrinolytic pathways using a recombinant endotoxin-binding protein (rBPI23).
    Blood. 1995 Jun 15;85(12):3437-43 PMID: 7780131
  23. Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein.
    J Infect Dis. 1995 Jul;172(1):144-51 PMID: 7797904
  24. Activity of lipopolysaccharide-binding protein-bactericidal/permeability-increasing protein fusion peptide in an experimental model of Pseudomonas sepsis.
    Antimicrob Agents Chemother. 1995 Dec;39(12):2813-5 PMID: 8593028
  25. Recombinant endotoxin-binding protein (rBPI23) attenuates endotoxin-induced circulatory changes in humans.
    J Inflamm. 1995;45(3):193-206 PMID: 8597874
  26. Inflammatory bowel disease is associated with increased mucosal levels of bactericidal/permeability-increasing protein.
    Gastroenterology. 1996 Mar;110(3):733-9 PMID: 8608882
  27. Antibiotic proteins of polymorphonuclear leukocytes.
    Eur J Haematol. 1996 May;56(5):263-77 PMID: 8641399
  28. Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis.
    QJM. 1996 Apr;89(4):259-65 PMID: 8733512
  29. Plasma bactericidal/permeability-increasing protein concentrations in critically ill children with the sepsis syndrome.
    Pediatr Infect Dis J. 1995 Dec;14(12):1087-91 PMID: 8745023
  30. Synergistic effect of a recombinant N-terminal fragment of bactericidal/permeability-increasing protein and cefamandole in treatment of rabbit gram-negative sepsis.
    Antimicrob Agents Chemother. 1996 Jan;40(1):65-9 PMID: 8787881
  31. Expression and characterization of cysteine-modified variants of an amino-terminal fragment of bactericidal/permeability-increasing protein.
    Protein Expr Purif. 1996 Aug;8(1):28-40 PMID: 8812832
  32. Bacterial infection induces nitric oxide synthase in human neutrophils.
    J Clin Invest. 1997 Jan 1;99(1):110-6 PMID: 9011564
  33. Antibacterial peptides and the outer membranes of gram-negative bacilli.
    J Med Microbiol. 1997 Jan;46(1):1-3 PMID: 9003734
  34. Peptide antibiotics.
    Lancet. 1997 Feb 8;349(9049):418-22 PMID: 9033483
  35. Antimicrobial peptides of leukocytes.
    Curr Opin Hematol. 1997 Jan;4(1):53-8 PMID: 9050380
  36. Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease.
    Gut. 1997 Jan;40(1):105-9 PMID: 9155585
  37. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution.
    Science. 1997 Jun 20;276(5320):1861-4 PMID: 9188532
  38. Lipopolysaccharide (LPS)-binding proteins BPI and LBP form different types of complexes with LPS.
    J Biol Chem. 1997 Jul 25;272(30):18682-5 PMID: 9228038
  39. Mechanisms of action of bactericidal/permeability-increasing protein BPI on reconstituted outer membranes of gram-negative bacteria.
    Biochemistry. 1997 Aug 19;36(33):10311-9 PMID: 9254630
  40. Bactericidal/permeability-increasing protein ameliorates hypercoagulability after hemorrhagic shock.
    Thromb Res. 1997 Aug 1;87(3):323-9 PMID: 9263399
  41. The genetic basis of microbial resistance to antimicrobial peptides.
    Methods Mol Biol. 1997;78:205-15 PMID: 9276306
  42. An opsonic function of the neutrophil bactericidal/permeability-increasing protein depends on both its N- and C-terminal domains.
    Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10973-8 PMID: 9380744
  43. Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis.
    Lancet. 1997 Nov 15;350(9089):1439-43 PMID: 9371168
  44. Role of the bactericidal/permeability-increasing protein in host defence.
    Curr Opin Immunol. 1998 Feb;10(1):45-9 PMID: 9523110
  45. PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance.
    Mol Microbiol. 1998 Mar;27(6):1171-82 PMID: 9570402
  46. The bactericidal/permeability-increasing protein (BPI) is present in specific granules of human eosinophils.
    Blood. 1998 Jun 15;91(12):4770-5 PMID: 9616176
  47. The molecular basis of chronic granulomatous disease.
    Springer Semin Immunopathol. 1998;19(4):417-34 PMID: 9618766
  48. Endotoxin interactions with lipopolysaccharide-responsive cells.
    Clin Infect Dis. 1999 Mar;28(3):476-81 PMID: 10194064
  49. Recombinant bactericidal/permeability-increasing protein (rBPI21) in combination with sulfadiazine is active against Toxoplasma gondii.
    Antimicrob Agents Chemother. 1999 Apr;43(4):758-62 PMID: 10103177
  50. Bactericidal/permeability-increasing protein (rBPI21) in patients with hemorrhage due to trauma: results of a multicenter phase II clinical trial. rBPI21 Acute Hemorrhagic Trauma Study Group.
    J Trauma. 1999 Apr;46(4):667-76; discussion 676-7 PMID: 10217232
  51. Phylogenetic perspectives in innate immunity.
    Science. 1999 May 21;284(5418):1313-8 PMID: 10334979
  52. Peptide antibiotics.
    Antimicrob Agents Chemother. 1999 Jun;43(6):1317-23 PMID: 10348745
  53. Antibiotic peptides from higher eukaryotes: biology and applications.
    Mol Med Today. 1999 Jul;5(7):292-7 PMID: 10377520
  54. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock.
    J Infect Dis. 1999 Nov;180(5):1584-9 PMID: 10515819
  55. Phagocytin: a bactericidal substance from polymorphonuclear leucocytes.
    J Exp Med. 1956 May 1;103(5):589-611 PMID: 13319580
  56. Impaired innate immunity in the newborn: newborn neutrophils are deficient in bactericidal/permeability-increasing protein.
    Pediatrics. 1999 Dec;104(6):1327-33 PMID: 10585984
  57. Cutting edge: cationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein.
    J Immunol. 2000 Jan 15;164(2):549-53 PMID: 10623792
  58. Enhancement of neonatal innate defense: effects of adding an N-terminal recombinant fragment of bactericidal/permeability-increasing protein on growth and tumor necrosis factor-inducing activity of gram-negative bacteria tested in neonatal cord blood ex vivo.
    Infect Immun. 2000 Sep;68(9):5120-5 PMID: 10948134
  59. LPS-binding proteins and receptors.
    J Leukoc Biol. 1998 Jul;64(1):25-32 PMID: 9665271
  60. Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung.
    J Clin Invest. 1998 Sep 1;102(5):874-80 PMID: 9727055
  61. Pharmacokinetics of a recombinant amino terminal fragment of bactericidal/permeability increasing protein (rBPI21) after liver surgery in rats and humans.
    Shock. 1998 Sep;10(3):161-6; discussion 167-8 PMID: 9744643
  62. Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes.
    J Biol Chem. 1978 Apr 25;253(8):2664-72 PMID: 344320
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
DOI
10.1128/AAC.44.11.2925-2931.2000
Email
levy_o@al.tch.harvard.edu
Published
2000-11-00
Pages
2925-31
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC101582
Subset
IM
Grants
NCRR NIH HHS · M01 RR002172 · United States
NIGMS NIH HHS · T32 GM007308 · United States
NIGMS NIH HHS · 5T32GM07308 · United States
NCRR NIH HHS · MO1RR02172 · United States
External Links
PubMed source DOI: 10.1128/AAC.44.11.2925-2931.2000 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2